Abstract
Idiopathic Pneumonia Syndrome (IPS) is a common complication after allo-SCT and results in high mortality rates. Conventional treatment for IPS typically includes supportive care and high-dose corticosteroids (CS). Data suggests that TNF-α is important in the pathogenesis of IPS and that the TNF-α inhibitor etanercept may be useful for IPS treatment. We performed a retrospective comparison of consecutive patients treated at our center for IPS with CS only from 1999 to 2003 (group 1, n=22) or CS plus etanercept from 2004 to 2007 (group 2, n=17). In all, 18% of patients in group 1 vs 53% in group 2 were successfully taken off respiratory support and discharged from the hospital (P=0.039). OS was significantly better for recipients of CS plus etanercept (P=0.003). The estimated survival at 28 days and 2 years after IPS was 36.4% (95% CI 17–56%) and 9.1% (95% CI 2–25%) for group 1 and 88.2% (95% CI 61–97%) and 18% (95% CI 4–38%) for group 2, respectively. Our retrospective comparison suggests that the addition of etanercept to CS for IPS improves response rates and OS. However, outcomes remain limited in both groups, highlighting the need for more effective interventions to treat early and late complications of IPS.
Similar content being viewed by others
References
Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH . NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147 (6 Pt 1): 1601–1606.
Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272–279.
Crawford SW, Longton G, Storb R . Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1993; 12: 225–231.
Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW . Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997; 63: 1079–1086.
Yanik G, Ho V, Levine J, White E, Braun T, Antin J et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112: 3073–3081.
Fukuda T, Hackman R, Guthrie K, Sandmaier B, Boeckh M, Maris M et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777–2785.
Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 395–400.
Afessa B, Peters S . Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 2008; 20: 227–233.
Keates-Baleeiro J, Moore P, Koyama T, Manes B, Calder C, Frangoul H . Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 285–289.
Cooke KR, Yanik G . Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 2004; 34: 753–765.
Clark JG, Madtes DK, Martin TR, Hackman RC, Farrand AL, Crawford SW . Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999; 27: 1800–1806.
Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230–3239.
Piguet PF, Grau GE, Collart MA, Vassalli P, Kapanci Y . Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 1989; 61: 37–45.
Shankar G, Bryson JS, Jennings CD, Kaplan AM, Cohen DA . Idiopathic pneumonia syndrome after allogeneic bone marrow transplantation in mice. Role of pretransplant radiation conditioning. Am J Resp Cell Mol Biol 1999; 20: 1116–1124.
Carlson M, West M, Coghill J, Panoskaltsis-Mortari A, Blazar B, Serody J . In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113: 1365–1374.
Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008; 112: 3073–3081.
Tun HW, Wallace KH, Grinton SF, Khoor A, Burger CD . Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transplant Proc 2005; 37: 4492–4496.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Bunin N, Aplenc R, Leahey A, Magira E, Grupp S, Pierson G et al. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias. Bone Marrow Transplant 2005; 35: 151–158.
Zhu K-E, Hu J-Y, Zhang T, Chen J, Zhong J, Lu Y-H . Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008; 81: 461–466.
Yanik G, Cooke K . The lung as a target organ of graft-versus-host disease. Semin Hematol 2006; 43: 42–52.
Hildebrandt G, Olkiewicz K, Corrion L, Chang Y, Clouthier S, Liu C et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 104: 586–593.
Frangoul H, Koyama T, Domm J . Etanercept for treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2009; 113: 2868–2869; author reply 2869.
Schoenfeld D, Bernard G . Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30: 1772–1777.
Frangoul H, Koyama T, Domm J . Etanercept for treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2009; 113: 2868–2869.
Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ et al. An Official American Thoracic Society Research Statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011; 183: 1262–1279.
Capizzi SA, Kumar S, Huneke NE, Gertz MA, Inwards DJ, Litzow MR et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 1299–1303.
Acknowledgements
This work was supported in part by the following grants: NIH K24 CA11787901 (DLP) and University of Pennsylvania Cancer Center Core Grant: P30-CA016520 (DFH, KST)
Author contributions: RT, NF, JD, MV and DLP designed research; RT, NF, JD, MV and DLP performed research; DFH and KST designed the statistical section and performed the statistical analyses; RT and DLP wrote the paper; all authors analyzed data and reviewed and edited the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Tizon, R., Frey, N., Heitjan, D. et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant 47, 1332–1337 (2012). https://doi.org/10.1038/bmt.2011.260
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.260
- Springer Nature Limited
Keywords
This article is cited by
-
Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2022)
-
Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study
International Journal of Hematology (2022)